Administrative Core

行政核心

• 批准号: 8233008
• 负责人: DAVID H WALKER
• 金额: $ 65.25万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-01 至 2014-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8233008
• 关键词: Animal Model; Animals; Anthrax disease; Applied Research; Arkansas; Bacillus anthracis spore; Bacteria; Categories; Cells; Collaborations; Communicable Diseases; Complement; Development; Diagnostic; Disease; Emerging Communicable Diseases; Funding; Genes; Germination; Goals; Grant; Individual; Infection; Infectious Diseases Research; Institution; Investigation; Knowledge; Lead; Leadership; Leg; Legal patent; Louisiana; Measurement; Medical; Names; National Institute of Allergy and Infectious Disease; Natural History; Nature; New Mexico; Nipah Virus; Oklahoma; Organism; Pathogenesis; Publications; RNA Viruses; Research; Research Personnel; Research Project Grants; Rift Valley fever virus; Role; Science; Strategic Planning; Structure; Sum; Texas; Therapeutic Agents; Toxin; Translational Research; Uncertainty; Universities; Venezuelan Equine Encephalitis Virus; Virus; Virus Diseases; Walkers; Work; biodefense; capsule; member; nonhuman primate; pathogen; programs; stem; success; vaccine development; virus genetics

The Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (WRCE) is located in DHHS Region VI, including Texas, New Mexico, Oklahoma, Arkansas, and Louisiana. Dr. David H. Walker is the PI and director for the WRCE. The University of Texas Medical Branch at Galveston (UTMB) is the lead institution. Academic institutions within the WRCE possess remarkable depth and breadth of scientific expertise related to Category A, B, and C priority pathogens and emerging and re-emerging infectious disease agents. From the very beginning, the WRCE leadership has strived to access this expertise and to make the WRCE a genuine cross-institutional Center involving all member states, not just in name or by concentrating projects at a few universities. The fact that over 100 project leaders at 34 different institutions have received funding from the WRCE is a testament to the plural nature of the WRCE program. The sense of collaboration and spirit of cooperation among investigators from traditionally competing institutions was previously unimaginable prior to the establishment of the WRCE in 2003 under Dr. Walker's guidance and strong leadership. The activities of the WRCE are firmly centered on supporting NIAID's Biodefense Research Agenda, and this application reaffirms our commitment to this strategy. The WRCE program is a success, as evaluated by a number of parameters that consider the whole Center as contributing more than the sum of its individual member institutions and investigators. In the assessment of the national RCE Program, several individual Center measurements were provided. They revealed that the WRCE ranked first in the number of organisms studied, total number of projects, number of Pis, additional non- RCE funding stemming from WRCE research, and number of patent applications as compared to the other individual Centers [1]. Our publication rate is also the one of the highest of the Centers. Since the WRCE was originally funded in September 2003, excellent progress has been made toward producing promising leads for biodefense countermeasures. WRCE translational research resulted in a wealth of significant basic biologic research as well, and the two are not mutually exclusive. Publications from WRCE researchers have resulted in new knowledge about the role of capsule in dissemination of inhalational anthrax, anthrax spore germination, rickettsial genes involved in phagosomal escape, the role of nonstructural genes in the replication of Rift Valley fever virus, the genetics of Nipah virus, and Venezuelan equine encephalitis virus host cell entry mechanisms, to name but a few. Additionally, the well characterized animal models developed by the WRCE Small Animal Core, Nonhuman Primate Core, and select project leaders all contributed knowledge about the natural history and pathogenesis of infections, and these investigations are an essential component for supporting applied research. The original WRCE application in 2003 had a very broad thematic structure in the strategic plan. The focus of the WRCE leadership was to fund the very best science and to take full advantage of the diversity of infectious disease and microbiologic expertise in our region. To date, the WRCE has funded 72 research projects and ten cores, including two trans-RCE cores that resided in our region. This work involved 30 different agents, including nine bacteria, 18 viruses, one protozoan, and two toxins. Given the yield in WRCE patents and publications, the institutions and investigators receiving funding, and projects advancing toward tangible products, this strategy served us very well during the first grant cycle. As the WRCE program matured, four themes emerged that logically encompassed the most productive projects that were likely to lead to biodefense countermeasures. The four themes are as follows: 1. Development of Therapeutic Agents for RNA Viruses 2. Platforms for Multiplexed Diagnostics for Category A-C Agents and Emerging Agents 3. Vaccine Development for Arboviral and Emerging Viral Diseases 4. Vaccine Development for Diseases Caused by Intracellular Bacteria These themes will no doubt serve to help us converge and synergize as we embark on the next leg of our research journey within the WRCE

西部地区生物防御和新兴传染病研究卓越中心 （WRCE）位于DHHS第六区，包括德克萨斯州、新墨西哥州、俄克拉荷马州、阿肯色州和路易斯安那州。博士 大卫·H.步行者是WRCE的PI和主管。德克萨斯大学医学分支加尔维斯顿 （UTMB）是牵头机构。WRCE内的学术机构拥有显着的深度和广度 与A、B和C类重点病原体以及新出现和重新出现的病原体有关的科学专门知识 传染病病原体。从一开始，WRCE的领导层就努力获得这种专业知识 并使WRCE成为一个真正的跨机构中心，涉及所有成员国，而不仅仅是名义上的， 将项目集中在几所大学。来自34个不同机构的100多名项目负责人 从WRCE获得资金证明了WRCE计划的多元性。感 来自传统竞争机构的研究人员之间的协作和合作精神， 在步行者博士的指导下于2003年建立WRCE之前， 强有力的领导。WRCE的活动是坚定地支持NIAID的生物防御研究为中心 这项申请重申了我们对这一战略的承诺。 WRCE计划是成功的，正如考虑整个中心的一些参数所评估的那样。 其贡献超过了其单个成员机构和研究人员的总和。在评估 在国家RCE计划中，提供了几个单独的中心测量结果。他们透露， WRCE在研究的生物体数量、项目总数、Pis数量、额外的非 来自WRCE研究的RCE资金，以及与其他研究相比的专利申请数量 个人中心[1]。我们的出版率也是最高的中心之一。由于WRCE是 最初于2003年9月获得资助，在生产有希望的铅方面取得了很大进展， 生物防御对策WRCE转化研究产生了大量重要的基础生物学 研究也是如此，两者并不相互排斥。WRCE研究人员的出版物导致 关于胶囊在传播吸入性炭疽、炭疽孢子 发芽，立克次体吞噬体逃逸相关基因，非结构基因在复制中的作用 裂谷热病毒、尼帕病毒和委内瑞拉马脑炎病毒的宿主细胞进入 机制，仅举几例。此外，WRCE开发的良好表征的动物模型 小动物核心，非人类灵长类动物核心，和选择的项目领导人都贡献了关于 感染的自然史和发病机制，这些调查是一个重要组成部分， 支持应用研究。 2003年最初的WRCE申请在战略计划中有一个非常广泛的主题结构。的 WRCE领导层的重点是资助最好的科学，并充分利用多样性 传染病和微生物学专业知识。到目前为止，WRCE已经资助了72项研究， 项目和十个核心，包括两个位于我们地区的trans-RCE核心。这项工作涉及30 包括9种细菌、18种病毒、1种原生动物和2种毒素。考虑到WRCE的产量 专利和出版物，接受资助的机构和研究人员，以及正在推进的项目， 由于这一战略是有形产品，因此在第一个赠款周期内，这一战略非常有效。作为WRCE计划 成熟后，出现了四个主题，逻辑上包含了最有可能 导致生物防御对策。这四个主题如下： 1. RNA病毒治疗药物的研究进展 2. A-C类病原体和新兴病原体的多重诊断平台 3.虫媒病毒和新发病毒性疾病的疫苗开发 4.细胞内细菌引起的疾病的疫苗开发 毫无疑问，这些主题将有助于我们在开展下一阶段工作时凝聚共识，发挥协同作用。 WRCE内部的研究之旅